Carisma Therapeutics Inc. (CARM) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.00 (+0.00%), Market cap $0.00B, P/E ratio 0.00, 52-week low–high $0.00 ~ $1.11.
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with
Financial statements, price targets, institutional (13F) holdings and related news for Carisma Therapeutics Inc. are updated in real time on BlackAll Trade.
Carisma Therapeutics Inc. trades at $0.00 (+0.00%). Real-time quotes and charts are available on BlackAll Trade.
Carisma Therapeutics Inc. has a market cap of about $0.00B. Its P/E ratio is 0.00.
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, whi